Ipamorelin vs GHRP-6: Comparación de secretagogos de hormona de crecimiento

Introduction: Selectivity vs Potency

Ipamorelin and GHRP-6 (Growth Hormone Releasing Peptide-6) both belong to the class of growth hormone secretagogues (GHSs) that stimulate GH release by activating the ghrelin receptor (GHS-R1a) on pituitary somatotrophs. Despite sharing the same receptor target, these two peptides represent opposite ends of the selectivity spectrum. Ipamorelin is celebrated for its clean, selective GH release, while GHRP-6 is known for its raw potency accompanied by broader hormonal effects. This comparison examines the research evidence to help clarify when and why one might be preferred over the other.

For individual compound profiles, see our articles on CJC-1295 and Ipamorelin and GHRP-6.

Comparison Table

Property	Ipamorelin	GHRP-6
Peptide Type	Pentapeptide (5 amino acids)	Hexapeptide (6 amino acids)
Sequence	Aib-His-D-2-Nal-D-Phe-Lys-NH2	His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
GH Release Potency	Moderate-high	High (one of the strongest GHRPs)
Selectivity	Highly selective for GH	Non-selective (affects multiple hormones)
Cortisol Elevation	None at standard research doses	Moderate increase (dose-dependent)
Prolactin Elevation	None at standard research doses	Mild-moderate increase
Appetite Stimulation	Minimal to none	Strong (intense hunger within 15-20 minutes)
Mechanism	GHS-R1a agonism (selective signaling bias)	GHS-R1a agonism (full agonist, activating all downstream pathways)
Half-Life	~2 hours	~20-30 minutes
GH Pulse Duration	~3 hours	~2 hours
Dose-Response Ceiling	Yes (GH response plateaus, preventing supraphysiological spikes)	Higher ceiling before plateau
Common Research Pairing	CJC-1295 (no DAC) / Mod GRF 1-29	CJC-1295 or GHRH analogs
Gastric Motility Effects	Minimal	Increases gastric motility and acid secretion
Clinical Trial Data	Phase 2 trials for postoperative ileus	Extensive preclinical; limited clinical trials

Mechanism Comparison: Why Selectivity Matters

Ipamorelin: Biased Agonism

Ipamorelin's selectivity is its defining feature. While it activates the same ghrelin receptor (GHS-R1a) as GHRP-6, research suggests it exhibits what pharmacologists call "biased agonism" or "functional selectivity." This means Ipamorelin preferentially activates certain intracellular signaling pathways downstream of the receptor while minimally engaging others.

Specifically, Ipamorelin appears to strongly activate the pathways leading to GH release from somatotrophs while only weakly activating the pathways responsible for cortisol release from the adrenal cortex, prolactin release from lactotrophs, and appetite stimulation via hypothalamic circuits. In clinical studies, Ipamorelin at doses up to 0.1 mg/kg did not significantly elevate cortisol, aldosterone, prolactin, or ACTH, even while producing robust GH release.

Another notable property is Ipamorelin's dose-response ceiling. Unlike some GHRPs, increasing the dose beyond a certain threshold does not continue to increase GH output, which provides a built-in safety mechanism against supraphysiological GH spikes.

GHRP-6: Full Agonism

GHRP-6 is a full agonist at the ghrelin receptor, meaning it activates all downstream signaling pathways without significant bias. This full agonism produces several effects beyond GH release:

• Appetite stimulation: GHRP-6 is one of the strongest appetite-stimulating peptides studied, producing intense hunger within 15-20 minutes of administration. This occurs because GHS-R1a activation in the hypothalamic arcuate nucleus stimulates the same appetite circuits as endogenous ghrelin.
• Cortisol elevation: GHRP-6 produces a dose-dependent increase in cortisol, likely through both direct adrenal effects and hypothalamic CRH stimulation. While the cortisol elevation is generally transient, it represents a confounding variable in research settings.
• Prolactin elevation: Mild to moderate increases in prolactin have been documented following GHRP-6 administration, potentially through effects on hypothalamic dopamine pathways.
• Gastric effects: GHRP-6 increases gastric motility and acid secretion, consistent with its mimicry of ghrelin's gut effects.

Practical Implications for Researchers

The selectivity difference between these two compounds has significant practical implications for research design:

Confounding variables: In studies where cortisol and prolactin levels must remain controlled, GHRP-6 introduces confounding hormonal changes that require additional controls. Ipamorelin's clean GH-only profile simplifies experimental design and data interpretation.

Appetite effects: For research in animal models where appetite changes could affect study outcomes (feeding behavior studies, metabolic research), GHRP-6's strong appetite stimulation is a significant consideration. Conversely, if appetite stimulation is the desired research endpoint, GHRP-6 provides a robust and reproducible model.

GH output: When maximum GH release is the primary endpoint and hormonal selectivity is less critical, GHRP-6's higher potency and higher dose-response ceiling may be advantageous.

Best Research Applications

Winner for Clean GH Research: Ipamorelin

When the research question specifically involves growth hormone effects and requires isolation of GH from other hormonal variables, Ipamorelin is the superior choice. Its selectivity ensures that observed outcomes can be attributed to GH elevation rather than confounding cortisol, prolactin, or appetite changes.

Winner for Maximum GH Output: GHRP-6

For studies requiring the highest achievable GH release from a ghrelin-receptor agonist, GHRP-6 delivers stronger GH pulses, particularly at higher doses where Ipamorelin's response has plateaued.

Winner for Appetite/Metabolism Research: GHRP-6

GHRP-6's potent appetite stimulation makes it a valuable tool for research involving ghrelin-mediated feeding behavior, gastric motility, or metabolic pathways related to hunger signaling.

Winner for Combination Protocols: Ipamorelin

The Ipamorelin + CJC-1295 (no DAC) combination is the most widely studied GHRH/GHRP pairing, prized for producing synergistic GH pulses while maintaining hormonal selectivity. GHRP-6 can also be paired with GHRH analogs, but the combination amplifies both GH release and the non-selective side effects.

Winner for Safety Profile: Ipamorelin

Ipamorelin's clinical trial data (Phase 2 for postoperative ileus) provides the most thorough human safety assessment among GHRPs, and its selectivity inherently reduces the risk of undesired hormonal effects.

For a comprehensive overview of all growth hormone secretagogues, see our Complete Guide to Growth Hormone Secretagogues.